N/A N=10 Clinical Feasibility Study, Implantable Tibial Nerve Stimulator (ITNS)
Overactive Bladder
Primary: Percent Change of Urinary Incontinence Frequency From Baseline to 13 Weeks — -89 percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=199 Standard PET/CT vs. Digital PET/CT
Cancer
Primary: Diagnostic Image Quality — 4.96; 4.30 score on a scale — p=<0.0000001
Phase 2 N=14 Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi
Rhinosinusitis · Chronic Polyposis
Primary: Change of Inflammation of the Nasal Mucosa and Paranasal Sinus — -2; -0.8 units on a scale
Phase 2 N=10 Histopathology Following CCH Injection
Characteristics of Subcutaneous Tissue
Primary: Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH — 2; 1; 1; 2 Participants
Phase 2 N=19 Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis
Rhinosinusitis
Primary: Change of Inflammation of the Nasal Mucosa and Paranasal Sinus — 0; -0.8 score on a scale
N/A N=128 AcQMap Objectively Visualize the Etiology of Recurrent AF Following a Failed AF Ablation
Recurrent Atrial Fibrillation
Primary: Number of Participants With Confirmation of Electrical Isolation of All Pulmonary Veins and Elimination/Modification of All Non-PV Targets — 99 Participants
Phase 2 N=21 Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
Carcinoma, Non-Small -Cell Lung · Ovarian Neoplasms · Small Cell Lung Carcinoma
Primary: Ph I: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Topotecan — 1.25 mg/m^2
Phase 1 N=42 Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in Cambodia
Vector Borne Diseases
Primary: Measurement of Change in Early and Late Innate Immune Responses Using Gene Expression and Flow Cytometry in Participants' Skin — 50; 5 % of total dendritic cells
Phase 2 N=578 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
Various Advanced Cancer
Primary: Neoadjuvant: Number of Participants With Drug-Related Select Adverse Events (AEs) — 3; 4; 3; 0 Participants
Phase 4 N=23 The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
Type 2 Diabetes
Primary: Change in Liver Fat Content — 14.8; 16.1; 10.7; 13.9 fat % — p=0.001
Phase 2 N=124 CSTC1 for Diabetic Foot Ulcers Phase II Study
Diabetic Foot Ulcer · Diabetes Mellitus · Wounds
Primary: Number of Participants With Complete Ulcer Closure During the Treatment Period — 32; 4 Participants
N/A N=1,089 A Virtual Navigation Intervention to Reduce Behavioral Health Admissions From Rural Emergency Departments
Depression · Anxiety · Substance Use Disorders
Primary: Assessing Hospital Admissions — 332; 326 Participants — p=0.27
Phase 2 N=222 Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
Partial Epilepsy
Primary: Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 Days — 55.6; 21.5 percent seizure reduction — p=<0.0001
Phase 1 N=3 A Phase I Trial of AZD3965 in Patients With Advanced Cancer
Adult Solid Tumor · Diffuse Large B Cell Lymphoma · Burkitt Lymphoma
Primary: MTD of AZD3965 — 10 mg (twice daily)
N/A N=108 Comparison of Depth of Sedation Performance Between SedLine and Comparator Device During General Anesthesia
Anesthesia
Primary: Correlation of Sedation Indices Performance Across Anesthesia Range — 0.8314 Pearson r